4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
4D Molecular Therapeutics, Inc. (FDMT) reports that State Street Corporation beneficially owned 2,469,425 shares of common stock, or 4.5% of the class, as of September 30, 2026. State Street reported shared voting power over 2,416,070 shares and shared dispositive power over 2,469,425 shares, with zero sole voting or dispositive power. It identifies SSGA Funds Management, Inc., State Street Global Advisors Europe Limited and State Street Global Advisors Trust Company as subsidiary investment advisers.
4D Molecular Therapeutics, Inc. (FDMT) Chief Legal Officer Scott Bizily exercised options for 1,635 shares of common stock on October 16, 2026, at an exercise price of $4.14 per share, then sold 1,635 shares at $12.84 per share. The transactions were made under a Rule 10b5-1 trading plan adopted January 13, 2026. His reported post-transaction option position covered 56,431 shares.
4D Molecular Therapeutics, Inc. President and Chief Executive Officer David Kirn reported two direct sales of Common Stock on October 5, 2026: 58,061 shares at a weighted average sale price of $12.9215 per share, and 272 shares at a weighted average sale price of $13.6104 per share.
Both sales were made under a Rule 10b5-1 trading plan adopted January 9, 2026. The 58,061-share sale was executed at prices from $12.61 to $13.60, and the 272-share sale at prices from $13.61 to $13.63.
4D Molecular Therapeutics, Inc. (FDMT) lists an anticipated sale by officer David Kirn of 58,333 shares of Class A common stock, with an aggregate market value of $753,662.36. The approximate sale date is October 5, 2026, and Goldman Sachs & Co. LLC is named as broker. The notice states that the shares are being sold in connection with a selling plan dated January 9, 2026, intended to comply with Rule 10b5-1(c).
4D Molecular Therapeutics, Inc. (FDMT) reported that the first patients have been enrolled across multiple sites in 4SIGHT, a global Phase 3 trial of 4D-150 for diabetic macular edema. The randomized, double-masked trial includes 514 treatment-naïve patients and compares intravitreal 4D-150 with aflibercept 2 mg.
All participants receive five aflibercept loading doses. The primary endpoint is non-inferiority in mean change in best corrected visual acuity at Week 52; secondary endpoints include injection burden and improvement on the diabetic retinopathy severity scale. The company reported FDA Regenerative Medicine Advanced Therapy designation for 4D-150 and alignment with the FDA and EMA on potential applications with the single 4SIGHT trial, based on data from SPECTRA and PRISM together with the two 4FRONT Phase 3 wet AMD trials. It also reported two-year SPECTRA data with a March 12, 2026 cutoff.
4D Molecular Therapeutics, Inc. (FDMT) reported that Chief Legal Officer Scott Bizily exercised options for 1,635 shares of common stock on September 16, 2026 at an exercise price of $4.14 per share and sold the same 1,635 shares at $13.65 per share pursuant to a Rule 10b5-1 trading plan adopted on January 13, 2026. Following the option exercise, Bizily held 58,066 options directly, and the option award continues to vest monthly from March 6, 2025 through the fourth anniversary of that date.
4D Molecular Therapeutics, Inc. (FDMT) reported that President and Chief Executive Officer David Kirn, who is also a director, sold 58,333 shares of common stock on September 14, 2026 in an open-market or private transaction at a weighted average price of $13.903 per share. The trade was executed under a Rule 10b5-1 trading plan adopted on January 9, 2026, with individual sale prices ranging from $13.43 to $14.15 per share, and left him holding 767,486 shares of common stock directly.
4D Molecular Therapeutics, Inc. (FDMT) reports that officer David Kirn has filed a Form 144 to sell up to 58,333 shares of Class A Common Stock through Goldman Sachs & Co. LLC, with an aggregate market value of $802,662.08, based on 55,244,211 shares outstanding of the same class. The shares were acquired from the issuer in a private transaction on December 15, 2020. The filing also lists prior sales of FDMT Class A Common Stock by Kirn over the past three months under a pre-established selling plan intended to comply with Rule 10b5-1(c).
4D Molecular Therapeutics, Inc. (FDMT) reported that its Chief Legal Officer, Scott Bizily, exercised options for 584 shares of common stock on September 1, 2026 at an exercise price of $6.49 per share and sold the same 584 shares at $14.00 per share. The option exercise and related sale were made under a Rule 10b5-1 trading plan adopted on January 13, 2026. Following the exercise, 2,959 option shares remain outstanding from this award, which vests in equal monthly installments over four years starting June 16, 2022.
4D Molecular Therapeutics, Inc. (FDMT) reported that President and Chief Executive Officer David Kirn exercised stock options for 50,000 shares of common stock at an exercise price of $4.14 per share, reducing that option position to 217,500 options remaining. He then sold a total of 69,076 common shares in open-market transactions on August 19, 2026, including 43,149 shares at a weighted average price of $15.3566 (within a range of $14.91–$15.84) and 25,927 shares at a weighted average price of $16.4173 (within a range of $15.97–$16.65). The filing states these trades were made pursuant to a Rule 10b5-1 trading plan adopted on January 9, 2026.